Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Cedar Grove Capital Management Paul Cerro | “Abivax ($ABVX) is a clinical-stage biotechnology company developing obefazimod, an oral small molecule candidate targeting ulcerative colitis and other inflammatory bowel diseases. The manager expanded the long holding despite quarterly weakness, maintaining that commercialization or an outright acquisition will drive value toward $170 to $200 per share. Economically, the value proposition rests on a largely de-risked Phase 3 drug asset addressing an enormous chronic immunology market. As global pharmaceutical giants face impending patent cliffs over the next decade, premium late-stage pipeline assets with favorable safety and efficacy profiles command significant strategic buyout premiums. Upcoming catalysts include regulatory submissions, commercialization milestones, and strategic buyout negotiations. Downside risks encompass regulatory approval delays, potential commercial execution challenges, and broad biotech multiple contraction from high discount rates.” | BULL | Q3 2026 Oct 5, 2026 | View Pitch |
Arquitos Capital Management Steven Kiel | “Abivax was added as a new 10% position during a market panic regarding illusory cancer risks in its Phase 3 trial data. Following the release of comprehensive safety data that cleared these concerns, the stock rebounded strongly and remains a highly attractive candidate for a future buyout.” | BULL | Q2 2026 Jul 22, 2026 | View Pitch |
Cedar Grove Capital Management Paul Cerro | “During the quarter, we increased our positions in Nektar Therapeutics (NKTR), Abivax SA (ABVX), The Oncology Institute (TOI), and Evolv Technologies (EVLV). NKTR and ABVX had good clinical data reported, which we talk about at the end, while EVLV delivered outstanding earnings and showed that the demand and growth for weapons detection systems is alive and well. There were two instances that, while fortunate, led to an unfortunate response in our P&L. One of the long special situation trades we had on was for Abivax SA (ABVX) and either the release of its ulcerative colitis (UC) maintenance drug data or the announcement of a buyout. No buyout has come (yet), but the company released the maintenance data on June 1. In essence, the drug showed above and beyond an efficacious response that any bull or sell-side research shop had expected, making it, at face value, an almost equal drug to JAK inhibitors on an efficacy level. However, the market got spooked that some cancer reports arose, and the company did a pretty poor job of explaining why those cancer reports did not show signs of being caused by the drug. An initial pop of >30% quickly became a sell the headline and the stock dropped ~50% at its worst in after-market trading. We did not agree with the market's interpretation of the data and found the opportunity to size up the position during the sharp drawdown. Fast forward to the end of June, and the company released updated safety data that showed the drug's cancer reports were indeed most likely not linked to the drug itself. The market rebounded well off the news, though the unfortunate part was that the stock did not rebound to its highs established earlier in the month for what is now arguably the best disease drug. While we got the positive news we've been waiting for, we unfortunately did not get to reap the rewards that we would have otherwise. ABVX will need more time.” | NEUTRAL | Q2 2026 Jul 15, 2026 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.